Pfizer Inc. $PFE Position Trimmed by First Financial Bank Trust Division

Key Points

• First Financial Bank Trust Division has reduced its holdings in Pfizer Inc. by 10.7%, holding 167,677 shares valued at $4.06 million at the end of the recent quarter.
• Pfizer reported $0.78 EPS for the last quarter, exceeding estimates, with revenue of $14.65 billion, up 10.3% year-over-year.
• The company announced a quarterly dividend of $0.43 per share, representing a 7.2% dividend yield and a payout ratio of 91.49%.

First Financial Bank Trust Division lessened its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 10.7% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 167,677 shares of the biopharmaceutical company's stock after selling 20,173 shares during the quarter. First Financial Bank Trust Division's holdings in Pfizer were worth $4,064,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. Gould Capital LLC grew its stake in shares of Pfizer by 97.2% in the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock valued at $27,000 after buying an additional 493 shares in the last quarter. GKV Capital Management Co. Inc. bought a new stake in Pfizer during the first quarter worth approximately $27,000. North Capital Inc. bought a new stake in Pfizer during the first quarter worth approximately $28,000. Bayforest Capital Ltd bought a new stake in Pfizer during the first quarter worth approximately $28,000. Finally, Bernard Wealth Management Corp. bought a new stake in Pfizer during the fourth quarter worth approximately $30,000. Hedge funds and other institutional investors own 68.36% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the company. HSBC decreased their target price on Pfizer from $27.00 to $26.00 and set a "buy" rating for the company in a research report on Monday, May 19th. Morgan Stanley upped their price target on Pfizer from $32.00 to $33.00 and gave the stock an "equal weight" rating in a report on Wednesday, August 6th. Jefferies Financial Group upped their price target on Pfizer from $32.00 to $33.00 and gave the stock a "buy" rating in a report on Wednesday, May 21st. Berenberg Bank cut their price target on Pfizer from $28.00 to $25.00 and set a "hold" rating for the company in a report on Thursday, May 29th. Finally, Citigroup upped their price target on Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a report on Wednesday, August 6th. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and an average target price of $28.12.

Pfizer Price Performance

Shares of PFE stock opened at $23.91 on Friday. The stock's fifty day moving average is $24.79 and its 200-day moving average is $24.30. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The stock has a market capitalization of $135.94 billion, a PE ratio of 12.72, a PEG ratio of 0.88 and a beta of 0.55. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $30.43.

Pfizer (NYSE:PFE - Get Free Report) last announced its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.58 by $0.20. The company had revenue of $14.65 billion for the quarter, compared to analysts' expectations of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business's revenue for the quarter was up 10.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Equities research analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th were issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 7.2%. The ex-dividend date was Friday, July 25th. Pfizer's dividend payout ratio is presently 91.49%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.